Yüklüyor......
Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer
Purpose: The effectiveness of nivolumab plus ipilimumab for advanced non-small cell lung cancer (NSCLC) has been demonstrated. Decisions have to be made about allocating healthcare resources. Economic evidence could support policy decisions to fund expensive interventions. The current analysis evalu...
Kaydedildi:
| Yayımlandı: | Front Pharmacol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8287729/ https://ncbi.nlm.nih.gov/pubmed/34290602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.573852 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|